间充质干细胞及其外泌体在药物性肝损伤治疗中的作用  

Role of mesenchymal stem cells and their exosomes in the treatment of drug-induced liver injury

作　　者：邢国静 罗龙龙 王丽菲 王顺娜 郑晓凤[3] 卢利霞 张久聪 XING Guojing;LUO Longlong;WANG Lifei;WANG Shunna;ZHENG Xiaofeng;LU Lixia;ZHANG Jiucong(Department of Gastroenterology,The 940th Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050,China;Department of Gastroenterology,General Hospital of Ningxia Medical University,Yinchuan 750001,China;Department of Gastroenterology,The Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院消化内科,兰州730050 [2]宁夏医科大学总医院消化内科,银川750001 [3]兰州大学第二医院消化内科,兰州730030

出　　处：《临床肝胆病杂志》2024年第3期633-638,共6页Journal of Clinical Hepatology

基　　金：甘肃省卫生健康行业科研项目(GSWSKY2023-34);第九四〇医院研究生导师专项课题(2023YXKY020);第九四〇医院青年培育项目(2021yxky054);中央高校优秀青年团队培育项目(31920220065);甘肃省非感染性肝病临床医学研究中心(21JR7RA017)。

摘　　要：药物性肝损伤(DILI)的发生率呈逐年上升趋势且损伤机制并不明确,针对DILI的治疗药物、肝脏支持系统及肝移植均有一定的局限性。因此,寻找更安全有效的治疗方法已成为当下研究的热点。间充质干细胞及其外泌体可通过减轻肝脏炎症反应,促进肝细胞增殖及再生、抗肝细胞凋亡,改善氧化应激和免疫调节等机制减轻肝损伤。本文就间充质干细胞及其外泌体在药物性肝损伤治疗中的作用进行简要综述,以期为进一步研究提供参考。The incidence rate of drug-induced liver injury(DILI)is increasing year by year with unknown mechanisms,and the treatment methods for DILI mainly include drugs,liver support systems,and liver transplantation,all of which have certain limitations.Therefore,the search for safer and more effective treatment methods has become a research hotspot at present.Studies have shown that mesenchymal stem cells and their exosomes can alleviate liver injury by reducing liver inflammation,promoting hepatocyte proliferation and regeneration,inhibiting the apoptosis of hepatocytes,improving oxidative stress,and regulating immunity.This article briefly reviews the role of mesenchymal stem cells and their exosomes in the treatment of DILI,so as to provide a reference for further research.

关 键 词：间质干细胞 外泌体 药物性肝损伤 

分 类 号：R575[医药卫生—消化系统]